AMWL
BEARISH
$4.87
Live
American Well Corporation · NYSE
Target $7.0
(+43.7%)
$3.71
52W Range
$12.95
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$79.73M
P/E
N/A
ROE
-37.0%
Profit margin
-42.8%
Debt/Equity
0.02
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
88%
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a low Price/Book and Price/Sales ratio suggesting potential value, persistent unprofitability, negative earnings momentum, and deteriorating revenue growth paint a bleak picture. Insider selling activity and a lack of analyst consensus further undermine confidence, while the company's long-term price performance has been catastrophic, down 99.3% over five years. Although the balance sheet shows low leverage and strong liquidity, these are overshadowed by systemic profitability and growth failures.
Key Strengths
Strong liquidity position with Current Ratio of 3.13 and Quick Ratio of 2.96 provides short-term financial flexibility.
Low Debt/Equity ratio of 0.02 indicates minimal reliance on debt financing and low financial risk from leverage.
Gross Margin of 52.59% reflects pricing power or efficient cost control at the production level.
Trading at deep value multiples: Price/Book of 0.31 and Price/Sales of 0.30 suggest potential undervaluation relative to assets and revenue.
Recent quarters show improved earnings surprise trends, beating estimates in 2 of the last 4 periods with an average beat of 18.31%.
Key Risks
Critically low Piotroski F-Score of 1/9 signals widespread financial weakness across profitability, leverage, and operating efficiency.
Persistent unprofitability with Profit Margin of -42.80% and ROE of -37.05% eroding shareholder value.
Revenue declining YoY by 7.80%, indicating shrinking top-line and potential loss of market relevance.
Insiders have been consistently selling shares, with $0.40M in net sales over the past 6 months, signaling lack of confidence.
Catastrophic long-term price performance: 5-year return of -99.3% raises structural concerns about business viability.
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
20
Weak
58
18
12
14
0
AI Verdict
Severely distressed with minimal near-term recovery prospects
Key drivers: Piotroski F-Score of 1/9, Negative profitability across all margins, Declining revenue and earnings momentum, Insider selling pressure, Historical price collapse
Confidence
90%
Value
58/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 0.31 suggests asset-based undervaluation
- Price/Sales of 0.30 is deeply discounted vs sector
Watchpoints
- No Graham Number or Intrinsic Value available due to unprofitability
- Negative earnings invalidate P/E and PEG interpretation
Future
18/100
Ref Growth rates
Positives
- Recent earnings surprises have been positive, indicating possible cost management improvements
Watchpoints
- Revenue Growth (YoY) of -7.80%
- Forward P/E of -1.00 indicates negative earnings expectations
- No clear path to profitability or growth recovery
Past
12/100
Ref Historical trends
Positives
- Some improvement in earnings surprises from 2023 to 2025
Watchpoints
- 5-year price return of -99.3%
- Consistent history of negative EPS
- Long-term deterioration in profitability metrics
Health
14/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current Ratio of 3.13 and Quick Ratio of 2.96 indicate strong short-term liquidity
Watchpoints
- Piotroski F-Score of 1/9 indicates systemic financial weakness
- ROE of -37.05% and ROA of -15.13% reflect capital destruction
- No Altman Z-Score available, but financial instability is evident
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.87
Analyst Target
$7.0
Upside/Downside
+43.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AMWL and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AMWL
American Well Corporation
Primary
|
-99.3% | -93.4% | -55.6% | -45.6% | +6.1% | +3.4% |
|
OM
Outset Medical, Inc.
Peer
|
-99.5% | -98.4% | -61.8% | -67.9% | +29.9% | +3.6% |
|
PARK
Park Dental Partners, Inc.
Peer
|
+75.8% | +75.8% | +75.8% | +75.8% | +5.4% | +1.2% |
|
QTI
QT Imaging Holdings, Inc.
Peer
|
-95.3% | -95.6% | -34.0% | -78.7% | +0.9% | +0.3% |
|
ASRT
Assertio Holdings, Inc.
Peer
|
-80.4% | -85.9% | -2.8% | -7.5% | -1.3% | -1.5% |
AMW
American Well Corporation
Primary
5Y
-99.3%
3Y
-93.4%
1Y
-55.6%
6M
-45.6%
1M
+6.1%
1W
+3.4%
OM
Outset Medical, Inc.
Peer
5Y
-99.5%
3Y
-98.4%
1Y
-61.8%
6M
-67.9%
1M
+29.9%
1W
+3.6%
PAR
Park Dental Partners, Inc.
Peer
5Y
+75.8%
3Y
+75.8%
1Y
+75.8%
6M
+75.8%
1M
+5.4%
1W
+1.2%
QTI
QT Imaging Holdings, Inc.
Peer
5Y
-95.3%
3Y
-95.6%
1Y
-34.0%
6M
-78.7%
1M
+0.9%
1W
+0.3%
ASR
Assertio Holdings, Inc.
Peer
5Y
-80.4%
3Y
-85.9%
1Y
-2.8%
6M
-7.5%
1M
-1.3%
1W
-1.5%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-1.0
PEG Ratio
N/A
P/B Ratio
0.31
P/S Ratio
0.3
EV/Revenue
-0.39
EV/EBITDA
1.51
Market Cap
$79.73M
Profitability
Profit margins and return metrics
Profit Margin
-42.8%
Operating Margin
-52.11%
Gross Margin
52.59%
ROE
-37.05%
ROA
-15.13%
Growth
Revenue and earnings growth rates
Revenue Growth
-7.8%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.02
Low debt
Current Ratio
3.13
Strong
Quick Ratio
2.96
Excellent
Cash/Share
$12.27
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-11
$N/A
2025-11-04
$-2.0
-12.0% surprise
2025-08-05
$-1.24
+28.9% surprise
2025-05-01
$-1.17
+38.0% surprise
Healthcare Sector Comparison
Comparing AMWL against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-37.05%
This Stock
vs
-88.14%
Sector Avg
-58.0%
(Below Avg)
Profit Margin
-42.8%
This Stock
vs
-16.28%
Sector Avg
+162.9%
(Superior)
Debt to Equity
0.02
This Stock
vs
2.66
Sector Avg
-99.2%
(Less Debt)
Revenue Growth
-7.8%
This Stock
vs
124.04%
Sector Avg
-106.3%
(Slower)
Current Ratio
3.13
This Stock
vs
4.47
Sector Avg
-29.9%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AMWL
American Well Corporation
|
BEARISH | $79.73M | - | -37.0% | -42.8% | $4.87 | |
|
OM
Outset Medical, Inc.
|
BEARISH | $79.66M | - | -106.2% | -68.3% | $4.35 | Compare |
|
PARK
Park Dental Partners, Inc.
|
NEUTRAL | $81.36M | - | -4.1% | -0.1% | $18.02 | Compare |
|
QTI
QT Imaging Holdings, Inc.
|
BEARISH | $83.45M | - | -% | -111.4% | $6.93 | Compare |
|
ASRT
Assertio Holdings, Inc.
|
BEARISH | $74.82M | - | -24.5% | -21.1% | $11.66 | Compare |
AMWL
American Well Corporation
BEARISH
Mkt Cap
$80M
P/E
-
ROE
-37.0%
Price
$4.87
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-02 | ZAMANSKY DMITRY | Chief Technology Officer | Sale | 6,243 | $30,279 |
| 2026-01-02 | MCNEICE PAUL FRANCIS | Officer | Sale | 384 | $1,862 |
| 2026-01-02 | GOTLIB PHYLLIS | Officer | Sale | 3,707 | $17,979 |
| 2025-12-18 | JACKSON DEBORAH C | Director | Sale | 612 | $2,883 |
| 2025-12-01 | MCNEICE PAUL FRANCIS | Officer | Sale | 113 | $458 |
| 2025-12-01 | GOTLIB PHYLLIS | Officer | Sale | 3,574 | $14,501 |
| 2025-10-01 | MCNEICE PAUL FRANCIS | Officer | Sale | 332 | $2,027 |
| 2025-10-01 | GOTLIB PHYLLIS | Officer | Sale | 4,959 | $30,282 |
| 2025-09-15 | JACKSON DEBORAH C | Director | Sale | 4,531 | $29,745 |
| 2025-09-03 | ZAMANSKY DMITRY | Chief Technology Officer | Sale | 25,605 | $173,407 |
| 2025-09-02 | JACKSON DEBORAH C | Director | Sale | 4,531 | $30,759 |
| 2025-09-02 | MCNEICE PAUL FRANCIS | Officer | Sale | 113 | $766 |
| 2025-09-02 | GOTLIB PHYLLIS | Officer | Sale | 4,781 | $32,422 |
| 2025-08-19 | JACKSON DEBORAH C | Director | Sale | 4,531 | $32,182 |
| 2025-08-13 | SCHOENBERG IDO | Chief Executive Officer | Stock Award | 50,000 | - |
ZAMANSKY DMITRY
Chief Technology Officer
2026-01-02
6,243 shares
·
$30,279
MCNEICE PAUL FRANCIS
Officer
2026-01-02
384 shares
·
$1,862
GOTLIB PHYLLIS
Officer
2026-01-02
3,707 shares
·
$17,979
JACKSON DEBORAH C
Director
2025-12-18
612 shares
·
$2,883
MCNEICE PAUL FRANCIS
Officer
2025-12-01
113 shares
·
$458
GOTLIB PHYLLIS
Officer
2025-12-01
3,574 shares
·
$14,501
MCNEICE PAUL FRANCIS
Officer
2025-10-01
332 shares
·
$2,027
GOTLIB PHYLLIS
Officer
2025-10-01
4,959 shares
·
$30,282
JACKSON DEBORAH C
Director
2025-09-15
4,531 shares
·
$29,745
ZAMANSKY DMITRY
Chief Technology Officer
2025-09-03
25,605 shares
·
$173,407
JACKSON DEBORAH C
Director
2025-09-02
4,531 shares
·
$30,759
MCNEICE PAUL FRANCIS
Officer
2025-09-02
113 shares
·
$766
GOTLIB PHYLLIS
Officer
2025-09-02
4,781 shares
·
$32,422
JACKSON DEBORAH C
Director
2025-08-19
4,531 shares
·
$32,182
SCHOENBERG IDO
Chief Executive Officer
2025-08-13
50,000 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
4 analysts
Morgan Stanley
2025-12-18
Equal-Weight
Equal-Weight
Wells Fargo
2025-11-05
Overweight
Overweight
Stifel
2025-11-05
Hold
Hold
Wells Fargo
2025-08-07
Overweight
Overweight
Past News Coverage
Recent headlines mentioning AMWL from our newsroom.
Newest → oldest
No matching news yet.